Fangzhou Inc. has issued a positive profit forecast for 2025, expecting full-year revenue to reach between RMB 3.5 billion and RMB 3.55 billion, representing approximately 30% year-on-year growth. The company also projects a net profit of RMB 7 million to RMB 10 million for the year, marking its first full year of comprehensive profitability. This improvement is attributed to the expansion of its AI-driven chronic disease management services and platform upgrades, which have attracted more physicians and patients. The transition to profitability was further supported by increased revenue scale and reduced equity-settled and share-based payments, reflecting a significant qualitative shift in Fangzhou’s business fundamentals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642998-en) on January 27, 2026, and is solely responsible for the information contained therein.